
Pegloticase injecatble
Form: Injectable (IV solution)
Strength: 8 mg/1.2 mL vial
Reference Brands: Krystexxa (US)
Category: Arthritis
Pegloticase injectable is approved in the US for the treatment of severe, refractory gout unresponsive to conventional therapies. In the EU, it is not widely approved; primarily marketed in the US under the brand Krystexxa (by Horizon Therapeutics). Regulatory dossiers demonstrate safety, efficacy, and manufacturing quality supported by clinical trial data. Both regions require detailed dossiers for initial approval and ongoing pharmacovigilance. For expert assistance with regulatory submissions, compliance, and registration, visit PharmaTradz. We facilitate efficient market access for pegloticase, ensuring adherence to European and US standards for safe, effective management of refractory gout, helping clients navigate complex regulatory landscapes seamlessly.
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Related Products
Colchicine tablest
Strength: 0.6 mg
Form: Tablet
Reference Brands: Colcrys(US)
View Details Get EnquiryFebuxostat tablets
Strength: 40 mg, 80 mg
Form: Oral Tablets
Reference Brands: Uloric(EU & US)
View Details Get EnquiryAllopurinol tablets
Strength: 100 mg, 300 mg
Form: Oral Tablets
Reference Brands: Aloprim(US & EU)
View Details Get EnquiryTriamcinolone Injectable (IM, intra-articular)
Strength: 40 mg/mL, 80 mg/mL, 80 mg/2 mL
Form: Injectable (IM, intra-articular)
Reference Brands: Kenalog(US & EU)
View Details Get Enquiry